Immune Modulation of T Cell Dysfunction in Tibia Fracture Model of Complex Regional Pain Syndrome 2260770

Abstract Introduction Complex regional pain syndrome (CRPS) is a debilitating chronic pain disorder with no effective treatments. Increasingly, aberrant immune regulation has been recognized in the induction and maintenance of CRPS pathology. Less is known about the role of T cells in CRPS. More recently, resident memory T cells (Trm), which help define the response of local tissues, have been implicated in autoimmune diseases. We hypothesize that systemic T cell dysfunction in CRPS contributes to pathological Trm development leading to disease development and persistence. Targeting T cell dysfunction by repurposing FDA approved immune modulating therapies may provide a novel treatment strategy for CRPS. Methods Mouse tibia fracture model (TFM) of CRPS was generated and pain hypersensitivity was measured by von Frey and Hargreaves. Hind limb skin, lymph node, bone marrow, and PBMCs were collected at different time points. T cell populations were analyzed by flow cytometry. Drugs targeting T cell dysfunction were evaluated in fracture mice at 5 weeks post-fracture. Nur77-GFP reporter and TCR KO mice were used for measuring activation and pain behavior. RNA-seq and cytokine production assays were performed to assess drug efficacy and functional T cell phenotyping. Results TFM mice demonstrate increased presence of phenotypic Trm populations in the skin compared to control mice. Trm demonstrate increased CD103+ populations. Signaling markers associated with Trm development were upregulated in pathological Trm, which were autoreactive measured by activation in GFP reporter mice. Pharmacological blockade of JAK signaling reduced autoreactive Trm, pain and cytokine signaling. Experiments with TCR KO models and RNA-seq studies are ongoing. Conclusion CRPS currently has no approved therapies. Increases in pathological autoreactive skin Trm populations may provide a novel avenue for therapeutic intervention, where blockade of signaling for Trm development and maintenance could prove beneficial for attenuating pain in CRPS. Funding Source 4RF1NS130481-02 Topic Categories Basic Autoimmunity (BA)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2026-07-28
DOI
https://doi.org/10.1093/jimmun/vkag141.980
Primary Topic
Pain Management and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immune Modulation of T Cell Dysfunction in Tibia Fracture Model of Complex Regional Pain Syndrome 2260770

Jason Wickman, Seena Ajit, Botros Shenoda
The Journal of Immunology
Pain Management and Treatment
article

Immune Modulation of T Cell Dysfunction in Tibia Fracture Model of Complex Regional Pain Syndrome 2260770

Jason Wickman, Seena Ajit, Botros Shenoda
article en

Abstract

Abstract Introduction Complex regional pain syndrome (CRPS) is a debilitating chronic pain disorder with no effective treatments. Increasingly, aberrant immune regulation has been recognized in the induction and maintenance of CRPS pathology. Less is known about the role of T cells in CRPS. More recently, resident memory T cells (Trm), which help define the response of local tissues, have been implicated in autoimmune diseases. We hypothesize that systemic T cell dysfunction in CRPS contributes to pathological Trm development leading to disease development and persistence. Targeting T cell dysfunction by repurposing FDA approved immune modulating therapies may provide a novel treatment strategy for CRPS. Methods Mouse tibia fracture model (TFM) of CRPS was generated and pain hypersensitivity was measured by von Frey and Hargreaves. Hind limb skin, lymph node, bone marrow, and PBMCs were collected at different time points. T cell populations were analyzed by flow cytometry. Drugs targeting T cell dysfunction were evaluated in fracture mice at 5 weeks post-fracture. Nur77-GFP reporter and TCR KO mice were used for measuring activation and pain behavior. RNA-seq and cytokine production assays were performed to assess drug efficacy and functional T cell phenotyping. Results TFM mice demonstrate increased presence of phenotypic Trm populations in the skin compared to control mice. Trm demonstrate increased CD103+ populations. Signaling markers associated with Trm development were upregulated in pathological Trm, which were autoreactive measured by activation in GFP reporter mice. Pharmacological blockade of JAK signaling reduced autoreactive Trm, pain and cytokine signaling. Experiments with TCR KO models and RNA-seq studies are ongoing. Conclusion CRPS currently has no approved therapies. Increases in pathological autoreactive skin Trm populations may provide a novel avenue for therapeutic intervention, where blockade of signaling for Trm development and maintenance could prove beneficial for attenuating pain in CRPS. Funding Source 4RF1NS130481-02 Topic Categories Basic Autoimmunity (BA)

The Journal of ImmunologyVol. 215(Supplement_1)
Abington Memorial Hospital (US), Jefferson Hospital (US), Drexel University (US)
Good health and well-being
Openalex Percentile: Top 7%
Pain Management and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.